There is abundant evidence that tumor-infiltrating CD8+ T cells contribute positively to
antitumor immunity; however, the role of tumor-infiltrating B cells (TIL-B) and plasma cells …

Checkpoint inhibitor therapy constitutes a promising cancer treatment strategy that targets
the immune checkpoints to re-activate silenced T cell cytotoxicity. In recent pivotal trials …

Background: There is conflicting evidence regarding the prognostic value of cytotoxic T cell
infiltration in breast cancer. The aims of this study were to detect the expression levels and …

CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …

Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …

Background Prostate cancer is one of the most common cancers in men and the fourth
leading cause of cancer mortality worldwide. Although major progress has been achieved in …

Background Biomarkers for response prediction to anti-programmed cell death 1 (PD-1)
immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma …

Immune checkpoint inhibitors (ICI) targeting programmed death 1 (PD-1), its ligand (PD-L1),
or cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown promising results against multiple …

Therapeutic approaches that engage immune cells to treat cancer are becoming
increasingly utilized in the clinics and demonstrated durable clinical benefit in several solid …

Simple Summary Melanoma affects over 300,000 people worldwide every year. Recent
advancements in therapeutic treatments for melanoma patients, such as targeted therapies …